회사 개요
Sotera Health Company operates as a prominent entity within the healthcare sector, specifically serving the diagnostics and research industry by providing sterilization solutions, laboratory testing, and advisory services across the United States, Canada, Europe, and international markets. The organization's operational scope is structured through three distinct business segments: Sterigenics, Nordion, and Nelson Labs, which collectively deliver outsourced services and products to healthcare facilities globally. In terms of scale, the company commands a substantial market capitalization of 43 억 달러 (4.33B 달러) and reports an annual revenue of 11 억 6 천만 달러 (1.16B 달러) based on trailing twelve-month figures, while employing a workforce of 3,000 명. These valuation and revenue metrics indicate that Sotera Health Company holds a significant position within its niche, reflecting substantial market presence and operational capacity relative to its peers in the sterilization and diagnostic testing sectors.
재무 건전성
The company's financial performance over the trailing twelve months demonstrates a revenue generation of 11 억 6 천만 달러 (1.16B 달러), with a net income of 7 천 790 만 달러 (77.94M 달러) and an EBITDA of 5 억 5 천 330 만 달러 (553.36M 달러). The substantial disparity between the 11 억 6 천만 달러 (1.16B 달러) revenue and the 7 천 790 만 달러 (77.94M 달러) net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, absorb a significant portion of gross revenue, resulting in a net income that is less than 10% of total sales. The enterprise generated free cash flow of 2 억 3 천 680 만 달러 (236.80M 달러), which signifies a robust capacity for financial flexibility, enabling the company to fund operations, service debt obligations, or pursue strategic investments without relying solely on external financing. Margin analysis highlights a gross margin of 55.5%, indicating efficient production and pricing power before overheads; an operating margin of 35.8%, which suggests strong control over operating expenses relative to sales; and a profit margin of 6.7%, reflecting the final profitability after all costs and taxes are deducted. The balance sheet shows a cash position of 3 억 4 천 490 만 달러 (344.90M 달러) against total debt of 22 억 8 천만 달러 (2.28B 달러), resulting in a debt-to-equity ratio of 375.56, which indicates a highly leveraged capital structure where debt obligations significantly exceed equity capitalization. Liquidity is supported by a current ratio of 2.46, suggesting that the company possesses more than twice the current assets necessary to cover its short-term liabilities, thereby indicating a comfortable margin of safety for immediate obligations. Return metrics show a return on equity of 15.4% and a return on assets of 8.2%, revealing that management generates a return on shareholders' equity that is nearly double the return on total assets, highlighting the efficiency of the equity base in generating profits despite the high leverage.
밸류에이션 평가
Valuation multiples indicate that the stock trades at a trailing P/E ratio of 56.44 and a forward P/E of 14.56, implying that the market expects a dramatic increase in earnings per share over the coming year, as the forward multiple is significantly lower than the historical average. The price-to-book ratio stands at 7.15, which suggests that the market is pricing the company at a substantial premium over its book value, potentially reflecting high growth expectations or intangible asset value not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 3.72 and an EV/EBITDA of 11.32 provide additional context, suggesting that while revenue-based valuation is elevated, earnings-based multiples align more closely with the forward earnings expectations. The stock has historically traded within a 52-week range of 9.53 달러 to 19.85 달러, and without a specific current price provided in the data, the valuation range establishes the volatility boundaries within which the share price has fluctuated over the past year. The beta value of 1.88 indicates that the stock price is significantly more volatile than the broader market, moving with nearly double the magnitude of market swings, which is consistent with a small-to-mid-cap stock in a specialized sector.
Growth & Income
Revenue growth for the trailing twelve months stood at 4.6%, while earnings growth surged to 175.4%, indicating that earnings are expanding at a rate far exceeding revenue growth, likely driven by margin expansion or one-time adjustments rather than top-line volume increases. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that the company retains all its earnings rather than distributing them to shareholders, a strategy typical for firms reinvesting capital into growth initiatives or debt reduction. This retention policy implies that the company prioritizes internal capital deployment over income distribution, which is common for companies with high growth potential or significant debt obligations that require cash reserves for servicing. The overall growth and income profile is characterized by exceptional earnings acceleration and revenue stability, supported by a lack of dividend payouts and a capital structure that relies heavily on retained earnings and external financing to fund operations and expansion.